ClinicalTrials.gg

Program

solrikitug

Also written as “NSI-8226”, “Solrikitug” and “MK-8266 TID, 2.4 mg”.

Its studies are mostly in Hypertension · Asthma · Eosinophilic Esophagitis · Dermatitis, Atopic, led by 2 companies.

Furthest: phase 2, since Dec 3, 20097 company-led studies, 1 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck40 open or runningphase 1since Dec 3, 2009Dec 3, 2009none ahead
Uniquity One (UNI)31 open or runningphase 2since Jul 3, 2024Jul 3, 2024Apr 30, 2027phase 2 · NCT06598462

Also a collaborator on its studies: devpro-biopharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 3, 2009First study: phase 1 study in HypertensionNew to MerckMerck · NCT01025791 · 25 enrolled
  2. Mar 26, 2010Phase 1 study in HypertensionMerck · NCT01096160 · 40 enrolled
  3. Nov 15, 2010Phase 1 study in HypertensionMerck · NCT01263314 · 16 enrolled
  4. Nov 19, 2012Phase 1 study in Dermatitis, AtopicMerck · NCT01732510 · 65 enrolled
  5. Jul 3, 2024Uniquity One (UNI)'s first study: phase 2 study in AsthmaNew to Uniquity One (UNI)Uniquity One (UNI) · NCT06496607 · 145 enrolled · United States
  6. Sep 13, 2024Phase 2 study in Eosinophilic EsophagitisUniquity One (UNI) · NCT06598462 · 184 enrolled · United States, Australia, Belgium and more
  7. Feb 26, 2025Phase 1 study in HealthyUniquity One (UNI) · NCT06868082 · 32 enrolled · Australia

Ahead

  1. Apr 30, 2027Primary completion: phase 2 study in Eosinophilic EsophagitisUniquity One (UNI) · NCT06598462

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06868082Healthy · Australia1CompletedUniquity One (UNI)Feb 2, 202632
NCT06598462Eosinophilic Esophagitis · United States, Australia, Belgium and more2Active, not recruitingUniquity One (UNI)Apr 30, 2027184
NCT06496607Asthma · United States2CompletedUniquity One (UNI)Jul 6, 2026145
NCT01732510Dermatitis, Atopic1TerminatedMerckOct 20, 201465
NCT01263314Hypertension1CompletedMerckFeb 1, 201116
NCT01096160Hypertension1CompletedMerckNov 1, 201040
NCT01025791Hypertension1CompletedMerckMay 14, 201025

How it is read

Names in the registry

  • “NSI-8226”, 3 entries
  • “Solrikitug”, 2 entries
  • “MK-8266 TID, 2.4 mg”, 2 entries
  • “Solrikitug Low Dose”, 1 entry
  • “Solrikitug Mid Dose”, 1 entry

Codes read as this program: MK8266.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.